The Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels
Phase 4
- Conditions
- Osteoporosis
- Interventions
- Registration Number
- NCT01765010
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
The purpose of this study is to compare the effect of inactive and active vitamin D on serum sclerostin and dickkopf1 levels.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Male
- Target Recruitment
- 88
Inclusion Criteria
- Healthy male volunteer older than 20 years
Exclusion Criteria
- Subjects with bone and mineral metabolism disorders
- Subjects with kidney or liver diseases
- Subjects with uncorrectable hypercalcemia or hypocalcemia
- Subjects with chronic gastrointestinal disorders or malabsorption
- Subjects taking medication related to bone loss
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description Placebo control Placebo Placebo control Cholecalciferol 1000IU Cholecalciferol Cholecalciferol 1000IU qd for 8 weeks alfacalcidol Alfacalcidol alfacalcidol 0.5ug qd for 8 weeks Calcitriol Calcitriol Calcitriol 0.25ug qd for 8 weeks
- Primary Outcome Measures
Name Time Method Change of serum sclerostin level 8 weeks later Change of serum Dickkopf1 level 8 weeks later
- Secondary Outcome Measures
Name Time Method Change of serum c-telopeptide level 8 weeks later Change of serum bone-specific alkaline phosphatase level 8 weeks later Change of serum calcium level 8 weeks later Change of serum parathyroid hormone level 8 weeks later
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do cholecalciferol, alfacalcidol, and calcitriol modulate Wnt signaling via sclerostin and DKK1 in osteoporosis?
What is the comparative efficacy of active vitamin D analogs versus standard bisphosphonates in reducing sclerostin/DKK1 levels for postmenopausal osteoporosis?
Which serum biomarkers predict differential response to inactive vs. active vitamin D formulations in osteoporosis patients?
What are the adverse event profiles of alfacalcidol and calcitriol compared to cholecalciferol in Phase 4 osteoporosis trials?
How does combination therapy with vitamin D analogs and RANKL inhibitors impact bone turnover markers in osteoporosis management?
Trial Locations
- Locations (1)
Seoul National University Medical School
🇰🇷Seoul, Korea, Republic of
Seoul National University Medical School🇰🇷Seoul, Korea, Republic ofChan Soo Shin, MD, PhDPrincipal InvestigatorJung Hee Kim, MDContact8220724839jhkxingfu@gmail.com